Wakez

Digital health startup using wearables and AI for sleep-time interventions and mental-health signals.

Cover Block

PUBLIC


Name	Wakez
Tagline	Digital health startup using wearables and AI for sleep-time interventions and mental-health signals.
Headquarters	Cluj-Napoca, Romania
Founded	2017
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+) [Adevărul, 2019]
Funding Label	Seed (total disclosed ~$1,610,000) [ZF IT Generation, July 2025]

Executive Summary

PUBLIC Wakez is a Romanian digital health startup attempting to convert passive sleep data from wearables into a therapeutic platform for mental health, a proposition that merits attention for its technical ambition and early-stage validation within the European innovation ecosystem [ZF IT Generation, July 2025]. Founded in 2017 by a group of medical students, the company has evolved from an app delivering subliminal vibrations for sleep improvement to a system that frames sleep-stage manipulation as a tool for antidepressant treatment [Adevărul, 2019] [Perplexity Sonar Pro Brief]. Its core differentiation rests on a claimed ability to apply haptic interventions during sleep without waking the user, leveraging what it terms "REM pressure" for therapeutic effect [WakeZ Use Cases, retrieved 2026].

The founding team's clinical orientation is a key asset, with co-founder Zaki Milhem serving as a practicing psychiatrist and lecturer at a major Cluj-Napoca medical university, lending credibility to the venture's health claims [Zaki Milhem - WakeZ - hack your sleep | LinkedIn, retrieved 2026]. To fund this pivot, Wakez secured approximately €1.5 million in seed capital from regional development agency ADR Nord-Vest in mid-2025, with a business model targeting both a direct-to-consumer subscription (€7-10/month) and institutional sales to mental-health clinics [ZF IT Generation, July 2025]. Over the coming year, the critical watchpoints will be the company's progress toward its forecasted €450,000 in revenue and its stated goal of achieving medical device registration in the European Union, milestones that would substantiate its transition from a wellness app to a regulated therapeutic tool.

Data Accuracy: YELLOW -- Core funding and team details are confirmed, but key product claims and revenue projections are sourced from a single regional outlet.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$1,610,000)

Company Overview

PUBLIC Wakez operates as a digital health startup from Cluj-Napoca, Romania, a region known for its technical talent and emerging tech ecosystem. The company was founded in 2017, originating from a project developed by a group of medical students aiming to apply clinical insights to consumer technology [Adevărul, 2019]. Its public narrative has evolved from a focus on general sleep improvement to a more targeted platform for mental health interventions, a shift reflected in its participation in the EIT Health InnoStars Grand Final in 2023 [EIT Health / YouTube, 2023].

A significant milestone was reached in July 2025, when the company secured €1.5 million (approximately $1.61 million) in a seed financing round led by the regional development agency ADR Nord-Vest [ZF IT Generation, July 2025]. This capital injection is intended to support product development and the pursuit of regulatory certification as a medical device within the European Union. The company's leadership includes co-founder Zaki Milhem, who holds a dual role as a practicing psychiatrist at a local hospital and a lecturer at the Iuliu Hațieganu University of Medicine and Pharmacy in Cluj-Napoca, providing a direct link between the startup's work and clinical practice [LinkedIn, retrieved 2026].

Data Accuracy: YELLOW -- Founding details and funding are corroborated by regional press; key team member is confirmed via LinkedIn. The 2019 article's claim about five medical student founders lacks named corroboration.

Product and Technology

MIXED Wakez's product is a digital health platform that uses consumer wearables, primarily the Apple Watch, to monitor sleep and deliver haptic interventions. The core proposition is to turn passive sleep data into a therapeutic tool, with a focus on improving sleep quality and, more recently, addressing mental health conditions like depression.

The platform operates through a smartphone application paired with a smartwatch. Its primary function is a smart alarm system that uses AI to analyze sleep stages and wake the user at an optimal time within a preset window. A more distinctive feature is its sleep-time intervention capability. The system applies subtle, subliminal vibration stimuli during specific sleep phases, such as REM sleep, with the stated goal of altering sleep architecture without waking the user [WakeZ Use Cases, retrieved 2026]. The company's later public framing positions this manipulation of "REM pressure" as a mechanism for antidepressant treatment [Perplexity Sonar Pro Brief]. The technology stack is inferred to involve sensor fusion algorithms processing data from the watch's accelerometer and heart rate sensor, combined with machine learning models for sleep stage classification and intervention timing.

Public descriptions also mention a cognitive forecasting feature, which provides users with predictions about their next day based on sleep data. The go-to-market model is a direct-to-consumer subscription, priced between €7 and €10 per month [ZF IT Generation, July 2025]. While the company aims for certification as a medical device in the European Union, its current public materials and app store presence frame it as a wellness product, creating a gap between its therapeutic claims and its regulatory status.

PUBLIC The market for sleep and mental-health technology is expanding beyond basic tracking, driven by a growing clinical recognition of sleep's role in mental health and the proliferation of consumer-grade sensing hardware. This shift creates a wedge for startups that can translate passive data into therapeutic interventions, moving from wellness into regulated care.

Third-party market sizing specific to sleep-time interventions for mental health is not publicly available. However, analogous markets provide a frame of reference. The global digital therapeutics market was valued at $5.1 billion in 2022 and is projected to reach $17.7 billion by 2027, according to a report by MarketsandMarkets [MarketsandMarkets, 2022]. Within this, the addressable market for sleep-related digital health tools is significant, with the consumer sleep technology market alone estimated at $15 billion (estimated) [McKinsey, 2023]. The serviceable obtainable market for a B2C subscription product like Wakez's, priced at €7-10 per month, would be a fraction of this broader landscape, targeting early adopters of wearable-based health solutions.

Demand is propelled by several converging tailwinds. There is a well-documented, persistent gap in access to mental healthcare globally, creating pressure for scalable, lower-cost interventions [WHO, 2022]. Concurrently, the installed base of capable sensing hardware,smartwatches and smartphones,has reached critical mass, providing a ubiquitous platform for data collection without requiring dedicated medical devices. A third driver is the increasing validation of sleep architecture, particularly REM sleep, as a biomarker and potential intervention point for conditions like depression, which lends clinical credibility to the underlying thesis [Nature Reviews Neuroscience, 2021].

Key adjacent and substitute markets define the competitive context. The primary adjacent market is general wellness and sleep-tracking, dominated by consumer apps and wearables from companies like Apple and Fitbit. A more direct substitute is the prescription digital therapeutic (PDT) market for mental health, where companies like Pear Therapeutics (now defunct) pioneered software-as-medicine pathways requiring regulatory approval. Wakez's positioning appears to straddle these, offering a consumer subscription while also framing its technology for therapeutic use, a path that implies future engagement with medical device regulations in the EU.

Regulatory pathways and macro forces present both a hurdle and a potential moat. In the European Union, where Wakez is based, achieving certification as a Class I or IIa medical device would be necessary to make any regulated treatment claims, a process that requires clinical validation and adds significant time and cost [European Commission, MDCG guidance]. Macro economically, consumer spending on health and wellness subscriptions has remained resilient, but purchasing decisions in this category are highly sensitive to perceived efficacy and data privacy assurances, which are not yet publicly demonstrated for the company.

Digital Therapeutics (Global) 2022 | 5.1 | $B
Digital Therapeutics (Global) 2027 | 17.7 | $B
Consumer Sleep Tech (Global) 2023 | 15 | $B

The projected near-doubling of the digital therapeutics market underscores the capital and clinical interest flowing into software-mediated care, though the leap from a wellness app to a reimbursed therapeutic is substantial.

Data Accuracy: YELLOW -- Market sizing relies on analogous, third-party reports; specific TAM for the company's niche is not confirmed.

Competitive Landscape

MIXED Wakez enters a crowded digital health arena by focusing on a specific, under-addressed intersection: using passive sleep-time interventions to generate mental-health signals.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Wakez	Wearable-first sleep intervention & mental-health signal detection via haptics/AI.	Seed (~€1.5M).	Targets REM pressure for antidepressant treatment; low-burden, sleep-time delivery.	[ZF IT Generation, July 2025]
WHOOP	Performance optimization via 24/7 physiological monitoring & recovery coaching.	Venture-backed; >$400M raised.	Strong brand in athletic/elite performance; subscription model with high user engagement.	[Failory]
Flow Neuroscience	Prescription home treatment for depression using brain stimulation (tDCS) & therapy app.	Venture-backed.	CE-marked medical device for MDD; clinical evidence base for its primary modality.	[Seedtable]
Ultrahuman	Metabolic health platform using continuous glucose monitoring (CGM) & wearables.	Venture-backed.	Focus on real-time metabolic data (blood glucose) as primary health signal.	[Seedtable]
Alphabeats	Mental fitness training using heart-rate coherence biofeedback via audio.	Early-stage.	Uses real-time heart-rate variability (HRV) feedback through headphones for stress reduction.	[Seedtable]
Neurable	Brain-computer interface (BCI) technology for cognitive state monitoring & control.	Venture-backed.	Enterprise-focused BCI for attention measurement; direct neural signal acquisition.	[Seedtable]

The competitive map splits into three tiers. First, general wellness and performance wearables like WHOOP and Oura dominate the consumer sleep-tracking layer, competing for wrist real estate and subscription dollars with broad feature sets. Second, adjacent mental-health therapeutic devices, such as Flow Neuroscience’s tDCS headset, operate in the regulated medical device space with a clear treatment claim for major depressive disorder (MDD). Third, a set of niche biofeedback platforms like Alphabeats and Neurable address specific physiological or neural signals but do not center the sleep period as the primary intervention window.

Wakez’s current defensible edge appears to be its chosen point of attack,the sleep state itself,and its proposed mechanism of action. The company’s focus on manipulating REM sleep via haptic stimuli to create an antidepressant effect is a specific technical hypothesis not broadly commercialized by the named competitors [WakeZ Use Cases, retrieved 2026]. This edge is perishable, however, as it relies on unproven clinical efficacy and first-mover execution in a niche. Should early data validate the REM pressure approach, the edge could solidify into a regulatory moat if Wakez secures medical device certification in the EU, a stated goal for 2025 [ZF IT Generation, July 2025]. Without that validation, the edge evaporates, reducing the product to another sleep-tracking app.

The exposure is twofold. In distribution, Wakez is vulnerable to incumbents with established consumer bases. WHOOP or Oura could replicate a haptic sleep-stage intervention as a software update, leveraging their existing hardware and millions of users. In therapeutic credibility, Flow Neuroscience and other certified devices hold a significant advantage with published clinical trials and regulatory clearance, making clinician adoption for depression treatment a steeper climb for an unproven newcomer. Wakez does not currently own a hardware channel or a clinical validation beachhead that would block these incursions.

The most plausible 18-month scenario hinges on evidence generation. If Wakez can publish pilot data demonstrating a measurable impact on depressive symptoms via its sleep intervention, it becomes an attractive acquisition target for a larger wellness or pharma company seeking a digital therapeutic pipeline. The winner in this case is a platform like Ultrahuman, which could integrate the validated sleep-modulation IP into its broader metabolic health ecosystem. The loser is a pure-play biofeedback app like Alphabeats, which may find its HRV-focused value proposition overshadowed by a modality that claims to work passively during sleep, requiring less user effort. Conversely, if Wakez fails to produce compelling data or secure device registration, its capital runway constrains further R&D, and it risks being relegated to a regional feature app, outmaneuvered by better-funded generalists.

Data Accuracy: YELLOW -- Competitor data drawn from secondary aggregators; Wakez's differentiation claims are from its own materials and one regional press interview.

Opportunity

PUBLIC The prize for Wakez is a position at the intersection of two large, underserved markets: consumer sleep technology and digital therapeutics for mental health, where a validated, non-invasive intervention could command significant recurring revenue from both individuals and healthcare systems.

The headline opportunity is to become the first clinically validated, wearable-native platform for sleep-modulated mental health treatment. This outcome is reachable because the company's core technical premise,using haptic stimuli to alter sleep architecture without waking the user,is already a documented function [WakeZ Use Cases, retrieved 2026]. The pivot from a general sleep-aid app to a therapeutic tool targeting depression via REM pressure suggests a strategic move towards a higher-value, evidence-based market. If Wakez can secure medical device registration in the EU, as it reportedly aims to do this year [ZF IT Generation, retrieved 2026], it would transition from a wellness product to a reimbursable therapeutic, fundamentally changing its addressable market and unit economics.

Growth could follow several distinct, high-conviction paths, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Clinical Pathway	Wakez becomes a prescribed digital therapeutic for mild-to-moderate depression in European health systems.	Successful CE marking as a Class IIa medical device and publication of a pilot clinical study.	The founding team includes a practicing psychiatrist and university lecturer [LinkedIn, retrieved 2026], providing clinical credibility and research access. The company is already framing its platform around REM pressure for antidepressant treatment [Perplexity Sonar Pro Brief].
Consumer Subscription Scale	The app achieves viral growth in the fitness/wellness wearable community, becoming a must-have sleep layer for WHOOP or Apple Watch users.	A strategic partnership or integration with a major wearable OEM.	The product is designed for smartwatch/smartphone sensing [Perplexity Sonar Pro Brief], and the €7-10 monthly subscription price [ZF IT Generation, July 2025] is competitive in the crowded consumer sleep app market. Early recognition from EIT Health provides a platform for visibility [EIT Health / YouTube, 2023].

Compounding for Wakez would be driven by a data-network effect in mental health. Each user generates proprietary sleep-stage and intervention-response data, which improves the predictive AI models for cognitive forecasting and depression subtyping. Better predictions increase intervention efficacy, which improves user retention and clinical outcomes. This, in turn, strengthens the case for medical reimbursement and attracts more clinical partners, creating a virtuous cycle where data improves the product, which expands the user base, which generates more data. The flywheel's first turn is the accumulation of initial user data to refine its algorithms, a process the current seed funding is meant to fuel.

The size of the win, should the clinical pathway scenario play out, can be framed by looking at comparable digital therapeutic acquisitions. For example, Pear Therapeutics, which developed prescription digital therapeutics for substance use and other disorders, was valued at over $1.6 billion at its SPAC merger in 2021 before later filing for bankruptcy. A more conservative but relevant benchmark is the market capitalization of wearable-focused health tech companies. WHOOP, a private competitor, was last valued at $3.6 billion in 2021 [Failory, retrieved 2026]. For Wakez, successfully capturing even a single-digit percentage of the global digital mental health market,projected to reach $20 billion by 2030 by some analysts,through a reimbursed therapeutic model could support a valuation in the hundreds of millions of euros (scenario, not a forecast).

Data Accuracy: YELLOW -- Core product mechanism is confirmed by company source; growth scenarios and market comparables are supported by cited reports, but clinical and commercial traction remain unverified.

Sources